IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Nov 19

PMID 22096557

Citations 44

Authors

Claudia Brehm

Sabine Huenecke

Andrea Quaiser

Ruth Esser

Melanie Bremm

Stephan Kloess

Jan Soerensen

Hermann Kreyenberg

Christian Seidl

Petra S A Becker

Heiko Muhl

Thomas Klingebiel

Peter Bader

Jakob R Passweg

Dirk Schwabe

Ulrike Koehl

Affiliations

Soon will be listed here.

Abstract

In an ongoing clinical phase I/II study, 16 pediatric patients suffering from high risk leukemia/tumors received highly purified donor natural killer (NK) cell immunotherapy (NK-DLI) at day (+3) +40 and +100 post haploidentical stem cell transplantation. However, literature about the influence of NK-DLI on recipient's immune system is scarce. Here we present concomitant results of a noninvasive in vivo monitoring approach of recipient's peripheral blood (PB) cells after transfer of either unstimulated (NK-DLI(unstim)) or IL-2 (1000 U/ml, 9-14 days) activated NK cells (NK-DLI(IL-2 stim)) along with their ex vivo secreted cytokine/chemokines. We performed phenotypical and functional characterizations of the NK-DLIs, detailed flow cytometric analyses of various PB cells and comprehensive cytokine/chemokine arrays before and after NK-DLI. Patients of both groups were comparable with regard to remission status, immune reconstitution, donor chimerism, KIR mismatching, stem cell and NK-DLI dose. Only after NK-DLI(IL-2 stim) was a rapid, almost complete loss of CD56(bright)CD16(dim/-) immune regulatory and CD56(dim)CD16(+) cytotoxic NK cells, monocytes, dendritic cells and eosinophils from PB circulation seen 10 min after infusion, while neutrophils significantly increased. The reduction of NK cells was due to both, a decrease in patients' own CD69(-) NCR(low)CD62L(+) NK cells as well as to a diminishing of the transferred cells from the NK-DLI(IL-2 stim) with the CD56(bright)CD16(+/-)CD69(+)NCR(high)CD62L(-) phenotype. All cell counts recovered within the next 24 h. Transfer of NK-DLI(IL-2 stim) translated into significantly increased levels of various cytokines/chemokines (i.e. IFN-γ, IL-6, MIP-1β) in patients' PB. Those remained stable for at least 1 h, presumably leading to endothelial activation, leukocyte adhesion and/or extravasation. In contrast, NK-DLI(unstim) did not cause any of the observed effects. In conclusion, we assume that the adoptive transfer of NK-DLI(IL-2 stim) under the influence of ex vivo and in vivo secreted cytokines/chemokines may promote NK cell trafficking and therefore might enhance efficacy of immunotherapy.

Citing Articles

Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.

Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M Transfus Med Hemother. 2025; 52(1):42-60.

PMID: 39944413 PMC: 11813277. DOI: 10.1159/000540962.

Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.

Zhu Y, Wang L, Jiang B, Wang Y, Wu Q, Hong S Future Sci OA. 2024; 10(1):2340186.

PMID: 39069888 PMC: 11290772. DOI: 10.2144/fsoa-2023-0135.

The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial.

Lee K, Yoon S, Gong J, Choi E, Kim H, Park C Leukemia. 2023; 37(4):807-819.

PMID: 36932165 DOI: 10.1038/s41375-023-01849-5.

Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis.

Cubukcu H, Yurdakul Mesutoglu P, Seval G, Beksac M Clin Exp Med. 2022; 23(6):2503-2533.

PMID: 36333526 DOI: 10.1007/s10238-022-00923-z.

A general toxicity and biodistribution study of human natural killer cells by single or repeated intravenous dose in severe combined immune deficient mice.

Park S, Yoon H, Gu E, Lee B, Kim Y, Jung J Toxicol Res. 2022; 38(4):545-555.

PMID: 36277368 PMC: 9532477. DOI: 10.1007/s43188-022-00138-0.

References

Middleton J, Patterson A, Gardner L, Schmutz C, Ashton B . Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood. 2002; 100(12):3853-60. DOI: 10.1182/blood.V100.12.3853. View

Passweg J, Stern M, Koehl U, Uharek L, Tichelli A . Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant. 2005; 35(7):637-43. DOI: 10.1038/sj.bmt.1704810. View

Farag S, Fehniger T, Ruggeri L, Velardi A, Caligiuri M . Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002; 100(6):1935-47. DOI: 10.1182/blood-2002-02-0350. View

Rizzieri D, Storms R, Chen D, Long G, Yang Y, Nikcevich D . Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16(8):1107-14. PMC: 3625653. DOI: 10.1016/j.bbmt.2010.02.018. View

Meller B, Frohn C, Brand J, Lauer I, Schelper L, von Hof K . Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2003; 31(3):403-7. DOI: 10.1007/s00259-003-1398-4. View

Lotze M, Matory Y, Ettinghausen S, Rayner A, Sharrow S, Seipp C . In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985; 135(4):2865-75. View

Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E . The trafficking of natural killer cells. Immunol Rev. 2007; 220:169-82. PMC: 7165697. DOI: 10.1111/j.1600-065X.2007.00563.x. View

Nguyen S, Dhedin N, Vernant J, Kuentz M, Al Jijakli A, Rouas-Freiss N . NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005; 105(10):4135-42. DOI: 10.1182/blood-2004-10-4113. View

ARONSON F, Libby P, Brandon E, Janicka M, Mier J . IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol. 1988; 141(1):158-63. View

10.

Kreyenberg H, Holle W, Mohrle S, Niethammer D, Bader P . Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience. Leukemia. 2003; 17(1):237-40. DOI: 10.1038/sj.leu.2402761. View

11.

Nishimura R, Baker J, Beilhack A, Zeiser R, Olson J, Sega E . In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008; 112(6):2563-74. PMC: 2532819. DOI: 10.1182/blood-2007-06-092817. View

12.

Dulphy N, Haas P, Busson M, Belhadj S, Peffault de Latour R, Robin M . An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol. 2008; 181(3):2227-37. DOI: 10.4049/jimmunol.181.3.2227. View

13.

Pegram H, Haynes N, Smyth M, Kershaw M, Darcy P . Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunol Immunother. 2010; 59(8):1235-46. PMC: 11030891. DOI: 10.1007/s00262-010-0848-7. View

14.

Huenecke S, Zimmermann S, Kloess S, Esser R, Brinkmann A, Tramsen L . IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother. 2010; 33(2):200-10. DOI: 10.1097/CJI.0b013e3181bb46f7. View

15.

Cassatella M, Gasperini S, Calzetti F, Bertagnin A, Luster A, McDonald P . Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol. 1997; 27(1):111-5. DOI: 10.1002/eji.1830270117. View

16.

Horne K, Woolley I . Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy. Inflamm Res. 2009; 58(8):431-5. DOI: 10.1007/s00011-009-0023-9. View

17.

Passweg J, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T . Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004; 18(11):1835-8. DOI: 10.1038/sj.leu.2403524. View

18.

Zimmermann S, Esser R, Rohrbach E, Klingebiel T, Koehl U . A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells. J Immunol Methods. 2005; 296(1-2):63-76. DOI: 10.1016/j.jim.2004.10.014. View

19.

Lanier L . NK cell recognition. Annu Rev Immunol. 2005; 23:225-74. DOI: 10.1146/annurev.immunol.23.021704.115526. View

20.

Passweg J, Koehl U, Uharek L, Meyer-Monard S, Tichelli A . Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2006; 19(4):811-24. DOI: 10.1016/j.beha.2006.06.004. View